Chardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Sell to Neutral with a price target of $60.00 (from $18.00).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE